Citius Pharmaceuticals stock carries LYMPHIR into fiscal Q3

Published on 10/06/2026 at 13:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citius Pharmaceuticals stock was last at USD 0.52 on October 5, 2026, after fiscal Q3 revenue of USD 1.5 million. LYMPHIR generated USD 7.1 million in nine-month revenue.

CTXR, US17322U3068, Illustration mit AI erstellt.

Citius Pharmaceuticals (ISIN US17322U3068) was last at USD 0.52 on Nasdaq on October 5, 2026, down USD 0.01, or 2.18 percent, from the previous close. The company enters the next reporting cycle with LYMPHIR commercialization as its main operating driver and fiscal Q3 revenue of USD 1.5 million.

LYMPHIR builds commercial revenue

Citius reported fiscal Q3 2026 revenue of USD 1.5 million and a diluted loss per share of USD 0.34, according to Webull on August 14, 2026. The figures show a commercial business that is generating sales while remaining loss-making during the product rollout.

For the first nine months of fiscal 2026, LYMPHIR produced USD 7.1 million in revenue and the business reported a 77 percent gross margin, while net loss reached USD 49.4 million, according to Quartr in its September 2026 conference summary. Revenue scale and cash use therefore remain closely linked to the pace of LYMPHIR adoption.

Analyst target stays far above price

Investing.com lists one covering analyst, a Strong Buy consensus, and an average, high, and low 12-month price target of USD 4.00. The page records H.C. Wainwright maintaining a Buy rating and the USD 4.00 target on August 19, 2026; measured against the USD 0.52 reference price, the target lies 669.23 percent above the price.

The market is pricing the company at USD 14.3 million, while the stock's October 5 range was USD 0.52 to USD 0.54 and trading volume was 120,565 shares. The 52-week range of USD 0.47 to USD 2.19 places the last price 76.26 percent below the yearly high, making execution of the commercial launch more important than the headline target alone.

Next results date is December 17

Nasdaq-listed CTXR has its next earnings report scheduled for December 17, 2026, according to Investing.com. That report should give investors a further checkpoint on LYMPHIR revenue, gross margin, and the funding required to support commercialization.

CTXR remains below its yearly high

Citius Pharmaceuticals was last at USD 0.52 on Nasdaq on October 5, 2026, with a market capitalization of USD 14.3 million and a daily change of negative 2.18 percent.